Research Use Only · Dosing data compiled from published literature · Not for human or veterinary use

Survodutide Dosage & Reconstitution

BI 456906, GLP-1/glucagon dual agonist. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: clinical.

1Set Up Your Mix

5 mg/mL · 5000 mcg/mL

Your Answer — Survodutide

10 mg in 2 mL
12Draw To This Line
0.12That's This Many mL
16Doses In The Vial
0102030405060708090100 U-100 syringe · 1 mL · 100 units draw to 12
10 mg ÷ 2 mL = 5 mg/mL  →  0.6 mg ÷ 5 mg/mL = 0.12 mL  →  × 100 = 12 units
Looks good. Draw to 12 units on a 1 mL syringe. That is an easy amount to measure, and this vial gives you 16 doses.
When to dose
Time of dayAny time of day. Weekly compounds should be kept to the same day each week.
FoodWith or without food — it makes no meaningful difference.

These are long-acting and reach steady state over weeks, so a single day’s timing has little effect. Consistency matters more than the hour.

2Week-By-Week Plan — Survodutide

Phase 2 escalation
WhenDoseHow OftenHow Many mLDraw ToNumber Of DosesPeptide Used
Weeks 1–4 0.6 mg once weekly 0.12 mL 12 u 4 2.4 mg
Weeks 5–8 1.2 mg once weekly 0.24 mL 24 u 4 4.8 mg
Weeks 9–12 2.4 mg once weekly 0.48 mL 48 u 4 9.6 mg
Weeks 13–16 3.6 mg once weekly 0.72 mL 72 u 4 14.4 mg
Week 17 onward
per 4 weeks from here on
6 mg once weekly 1.2 mL 120 u ⚠ 4 24 mg
Time until the top dose
16 weeks
Peptide used getting there
31.2 mg
Vials you'll need
4 × 10 mg
Once you're at the top dose
24 mg / 4 wk · 2.4 vials
Where this plan came from
A clinical trial schedule
Where this came from: Lancet Diabetes & Endocrinology phase 2 programme. The phase 2 programme tested both rapid and gradual escalation arms; the steps below follow a four-week cadence toward the 6.0 mg arm.

3Common Doses — Survodutide

worked out for your mix
LevelDoseHow OftenHow Many mLDraw ToDoses In Vial
Initiation 0.6 mg once weekly 0.12 mL 12 u 16 doses
Step 2.4 mg once weekly 0.48 mL 48 u 4 doses
Step 3.6 mg once weekly 0.72 mL 72 u 2 doses
Trial max 6 mg once weekly 1.2 mL 120 u ⚠ 1 doses
Please read this. These numbers come from published research. They are here as reference, not as instructions. A lot of them come from lab studies rather than studies in people, and some of these peptides have never been given to a person at all.

About Survodutide

Metabolic / Incretin
Also known as
BI 456906, GLP-1/glucagon dual agonist
Class
Metabolic / Incretin
Route
Subcutaneous
Half-life
~6 days
Evidence tier
Clinical

A dual GLP-1/glucagon receptor agonist in phase 3, with notable phase 2 results in MASH as well as obesity.

Buy Survodutide

Common Questions — Survodutide

How much bacteriostatic water do I add to a 10 mg vial of Survodutide?

Adding 2 mL of bacteriostatic water to a 10 mg vial gives 5 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.

What dose of Survodutide is used in research?

Published and reported figures for Survodutide run from 0.6 mg to 6 mg, typically once weekly.6 mg to 6 mg, typically once weekly.6 mg to 6 mg, typically once weekly. This site lists each figure with the source it came from rather than giving a single recommended number.

How many units on the syringe is a 0.6 mg dose of Survodutide?

At 5 mg/mL, a 0.6 mg dose is 12 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 16 doses.

How strong is the evidence behind these Survodutide doses?

Survodutide is graded clinical. Human trial or approved-label dosing has been published for this compound. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.

Is there a Survodutide titration schedule?

Yes — Phase 2 escalation. The week-by-week table on this page converts each step into the exact amount to draw for your mix.

Where These Numbers Come From

Clinical — Human trial or approved-label dosing published
Survodutide for the treatment of obesity — phase 2 randomised trial le Roux CW, et al. The Lancet Diabetes & Endocrinology, 2024
Source of the 0.6–6.0 mg escalation arms.
Find on PubMed ↗
Survodutide in metabolic dysfunction-associated steatohepatitis Sanyal AJ, et al. New England Journal of Medicine, 2024
MASH endpoint data at the same dose range.
Find on PubMed ↗

Newest Studies —

Not reviewed by us. This list is pulled straight from Europe PMC as papers are published. Nobody has checked whether these are any good, or whether they change anything above. The dose numbers on this page only ever change after a person reviews the evidence.

Other metabolic / incretin peptides

Compounds in the same class, or browse the full catalogue.

5-Amino-1MQ

A small-molecule NNMT inhibitor rather than a true peptide. Research data show reduced adiposity in diet-induced obesity models. D…

All 72 peptides

Every compound compared in one table: dose range, how often, half-life and evidence tier.

Need this on one page to print, screenshot or send?

Make a dose card →